Gilead SciencesGILD
About: Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Employees: 17,600
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
46% more call options, than puts
Call options by funds: $1.16B | Put options by funds: $795M
22% more first-time investments, than exits
New positions opened: 180 | Existing positions closed: 147
14% more repeat investments, than reductions
Existing positions increased: 817 | Existing positions reduced: 717
2.15% more ownership
Funds ownership: 83.66% [Q1] → 85.8% (+2.15%) [Q2]
1% more capital invested
Capital invested by funds: $117B [Q1] → $118B (+$1.57B) [Q2]
1% less funds holding
Funds holding: 1,983 [Q1] → 1,969 (-14) [Q2]
39% less funds holding in top 10
Funds holding in top 10: 51 [Q1] → 31 (-20) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
RBC Capital Brian Abrahams | 14%downside $98 | Sector Perform Maintained | 8 Aug 2025 |
UBS Colin Bristow | 2%downside $112 | Neutral Maintained | 8 Aug 2025 |
Truist Securities Asthika Goonewardene | 11%upside $127 | Buy Upgraded | 8 Aug 2025 |
Needham Joseph Stringer | 17%upside $133 | Buy Upgraded | 25 Jul 2025 |
Financial journalist opinion
Based on 43 articles about GILD published over the past 30 days
